Aberdeen Group plc Grows Position in Dyne Therapeutics, Inc. $DYN

Key Points

• Aberdeen Group plc increased its stake in Dyne Therapeutics by 53.8% in Q2, holding 483,963 shares valued at approximately $4.6 million.
• Dyne Therapeutics recently received varying analyst ratings, with Royal Bank of Canada lowering its price target to $23 and Raymond James raising it to $35, resulting in an average rating of "Moderate Buy".
• Dyne Therapeutics, which focuses on therapies for genetically driven muscle diseases, reported an EPS of ($0.97), beating analyst expectations of ($0.99).

Aberdeen Group plc boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 53.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 483,963 shares of the company's stock after buying an additional 169,377 shares during the period. Aberdeen Group plc owned approximately 0.43% of Dyne Therapeutics worth $4,607,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its position in Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after buying an additional 2,446 shares in the last quarter. Quarry LP bought a new position in Dyne Therapeutics during the 1st quarter valued at approximately $47,000. E Fund Management Co. Ltd. increased its position in Dyne Therapeutics by 16.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after buying an additional 1,923 shares in the last quarter. KLP Kapitalforvaltning AS increased its position in Dyne Therapeutics by 39.4% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 15,200 shares of the company's stock valued at $145,000 after buying an additional 4,300 shares in the last quarter. Finally, 111 Capital bought a new position in Dyne Therapeutics during the 2nd quarter valued at approximately $147,000. Institutional investors own 96.68% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on DYN. Royal Bank Of Canada reduced their price objective on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, July 29th. Raymond James Financial raised Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price objective for the company from $31.00 to $35.00 in a research report on Monday, August 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Wednesday, October 8th. Chardan Capital reduced their target price on Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a report on Tuesday, July 29th. Finally, Oppenheimer reissued a "market perform" rating and issued a $13.00 target price on shares of Dyne Therapeutics in a report on Friday, October 10th. Four research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and an average target price of $34.07.

Dyne Therapeutics Stock Performance

DYN stock opened at $16.42 on Friday. The company has a market cap of $2.34 billion, a P/E ratio of -4.25 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $35.77. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. The stock's fifty day moving average price is $13.22 and its 200-day moving average price is $11.38.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Activity

In other news, CEO John Cox sold 2,640 shares of the firm's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer directly owned 199,539 shares in the company, valued at $2,675,817.99. This trade represents a 1.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.14% of the stock is currently owned by company insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.